LIBTAYO 350 mg concentrate for solution for infusion.
ETOP 27-23 ARCH
Phase 3 small_molecule active
Quick answer
LIBTAYO 350 mg concentrate for solution for infusion. for Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1% is a Phase 3 program (small_molecule) at Partner Therapeutics Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Partner Therapeutics Limited
- Indication
- Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active